Literature DB >> 23781968

Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment.

Abraham C J Stork, Nicolette C Notermans, Alexander F J E Vrancken, David R Cornblath, W-Ludo van der Pol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23781968     DOI： 10.1111/jns5.12018

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN： 1085-9489            Impact factor:   3.494


× No keyword cloud information.
  4 in total

Review 1.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

3.  Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome.

Authors:  Giuliana Galassi; Francesca Testa; Francesca Bianchi; Gianni Cappelli; Annalisa Chiari
Journal:  CEN Case Rep       Date:  2017-06-20

4.  Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy.

Authors:  Ruben Herrendorff; Pascal Hänggi; Hélène Pfister; Fan Yang; Delphine Demeestere; Fabienne Hunziker; Samuel Frey; Nicole Schaeren-Wiemers; Andreas J Steck; Beat Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-17       Impact factor: 11.205
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.